2015
CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes
Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia 2015, 58: 1167-1174. PMID: 25773405, PMCID: PMC4416994, DOI: 10.1007/s00125-015-3559-y.Peer-Reviewed Original ResearchConceptsC-peptide levelsType 1 diabetesHigher C-peptide levelsC-peptideGlucose levelsTime pointsGlucose valuesMixed meal tolerance testAims/hypothesisThe aimCGM glucose levelsC-peptide responseWeeks of diagnosisOnset of diabetesLower glucose variabilityConclusions/interpretationInMethodsA secondary analysisSensor glucose levelsCGM glucose valuesAdditional time pointsHypothesisThe aimGlucose variabilityTolerance testContinuous glucose monitoring dataInsulin secretionCGM metrics
2014
Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia
Mauras N, Mazaika P, Buckingham B, Weinzimer S, White NH, Tsalikian E, Hershey T, Cato A, Cheng P, Kollman C, Beck RW, Ruedy K, Aye T, Fox L, Arbelaez AM, Wilson D, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer KK, Reiss AL. Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia. Diabetes 2014, 64: 1770-1779. PMID: 25488901, PMCID: PMC4407847, DOI: 10.2337/db14-1445.Peer-Reviewed Original ResearchConceptsWhite matter growthControl subjectsAge-matched control subjectsType 1 diabetesHigh-resolution structural MRIWhite matter areasWhite matter volumeYoung childrenContinuous glucose monitoringGray matter regionsNondiabetic childrenChronic hyperglycemiaExecutive function scoresFunction scoresGlucose variabilityMatter volumeChildren ages 4Comprehensive neurocognitive testsBrain regionsLongitudinal assessmentType 1Structural MRIHyperglycemiaDiabetesMatter regions
2012
Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, . Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemia
2011
Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study
Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatric Diabetes 2011, 13: 6-11. PMID: 21722284, DOI: 10.1111/j.1399-5448.2011.00793.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented pump therapyA1C valuesSAP groupMDI groupPump therapyA1C targetsSAP therapyHyperglycemic excursionsMultiple daily injection therapyBaseline A1C valuesRisk of hypoglycemiaA1C reductionInjection therapyPediatric patientsGlycemic excursionsGlucose variabilityMDI therapyGlycemic variabilityLower AUC valuesTreatment groupsTherapyCGM studiesDiabetesAUC valuesNew-generation diabetes management: glucose sensor-augmented insulin pump therapy
Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Review Of Medical Devices 2011, 8: 449-458. PMID: 21728731, PMCID: PMC3177536, DOI: 10.1586/erd.11.22.Peer-Reviewed Original ResearchConceptsSensor-augmented insulinSensor-augmented insulin pump therapyCommon chronic disorderInsulin pump therapyContinuous subcutaneous insulin infusion systemsInsulin infusion systemField of diabetesPump therapyGlucose variabilityChronic disordersChallenging diseaseContinuous glucose monitorDelivery of insulinDiabetes managementInfusion systemTherapyInsulin deliveryTechnologic advancesInsulin
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetes